Pradžia › Kepenų ligos › Virginia
Kepenų ligos klinikiniai tyrimai Virginia
6 tyrimai dėl Kepenų ligos ieško dalyvių vietose Virginia.
Miestai Virginia
Oficialus tyrimo tekstas (anglų kalba)
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-09 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- ir dar 1
Renkami dalyviai3 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-03 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-03 · NCT06419374A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Richmond
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-17 · NCT06600321Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
- Hunter Holmes McGuire VA Medical Center, Richmond
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-09 · NCT06464952A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Virginia Commonwealth University, Richmond
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-12-15 · NCT06619561Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.